Human Papillomavirus negative but dyskaryotic cervical cytology: Re-analysis of molecular testing

Journal of Clinical Virology

Volumn 44, Issue 4, 2009, Pages 322-324

  Peevor, R ^a   Bowden, S ^a   Jones, J ^a   Fiander, A N ^a   Hibbitts, S ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Cervical screening; Dyskaryosis; HPV negative; HPV testing; Human Papillomavirus

Indexed keywords

VIRUS DNA;

ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DNA MICROARRAY; DYSKARYOSIS; FALSE NEGATIVE RESULT; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROBIOLOGICAL EXAMINATION; NONHUMAN; PRIORITY JOURNAL; SCREENING; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; WART VIRUS;

CELL NUCLEUS; CERVIX UTERI; DIAGNOSTIC ERRORS; FEMALE; GREAT BRITAIN; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; WALES;

EID: 62949112179     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2009.01.015     Document Type: Article

References (12)

1. Hibbitts S., Jones J., Powell N., Dallimore N., McRea J., Beer H., et al. Human papillomavirus prevalence in women attending routine cervical screening in South Wales, UK: a cross-sectional study. Br J Cancer 99 December (11) (2008) 1929-1933
2. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 1 (1999 Sep) 12-19
3. Munoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 19 October (1-2) (2000) 1-5
4. McCredie M.R., Sharples K.J., Paul C., Baranyai J., Medley G., Jones R.W., et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 9 May (5) (2008) 425-434
5. Cuzick J., Clavel C., Petry K.U., Meijer C.J., Hoyer H., Ratnam S., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119 September (5) (2006) 1095-1101
6. Cuzick J., Szarewski A., Cubie H., Hulman G., Kitchener H., Luesley D., et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 362 December (9399) (2003) 1871-1876
7. Sherman M.E., Lorincz A.T., Scott D.R., Wacholder S., Castle P.E., Glass A.G., et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 95 January (1) (2003) 46-52
8. Bulkmans N.W., Berkhof J., Rozendaal L., van Kemenade F.J., Boeke A.J., Bulk S., et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370 November (9601) (2007) 1764-1772
9. Jacobs M.V., Snijders P.J., van den Brule A.J., Helmerhorst T.J., Meijer C.J., and Walboomers J.M. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 35 March (3) (1997) 791-795
10. Bishop J.W., Bigner S.H., Colgan T.J., Husain M., Howell L.P., McIntosh K.M., et al. Multicenter masked evaluation of AutoCyte PREP thin layers with matched conventional smears. Including initial biopsy results. Acta Cytol 42 January-February (1) (1998) 189-197
11. Sherman M.E., Mendoza M., Lee K.R., Ashfaq R., Birdsong G.G., Corkill M.E., et al. Performance of liquid-based, thin-layer cervical cytology: correlation with reference diagnoses and human papillomavirus testing. Mod Pathol 11 September (9) (1998) 837-843
12. Cuzick J., Arbyn M., Sankaranarayanan R., Tsu V., Ronco G., Mayrand M.H., et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26 August (Suppl. 10) (2008) K29-K41